News

September 13, 2016

Scrip

Indication-Based Pricing Could Be Windfall for Interleukin Inhibitors

By Emily Hayes

Express Scripts’ plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.